Equibles does not estimate personal net worth.
Get an email with a short summary when Vertex Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get VRTX alertsCharlie Wagner is recorded as CFO at Vertex Pharmaceuticals Inc (VRTX). Charlie Wagner has spoken on 12 earnings calls and 3 other investor events across 1 company, most recently for Vertex Pharmaceuticals Inc on July 6, 2026. Vertex Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vertex Pharmaceuticals Inc includes Dr. Reshma Kewalramani (CEO), Reshma Kewalramani (CEO and Board Member), Dr. Jeffrey M. Leiden (Chairman) and 7 others.
“Vertex will acquire all outstanding shares of Crenetics common stock for $85 per share in cash. The total equity value is approximately $10 billion, or $8.8 billion net of estimated cash acquired.”
“Yeah, listen, we continue to be really excited about CF, very proud of the leadership position that we've built over the last 20 years. you know we have an outstanding portfolio of medicines and hundreds of thousands of patient years of experience at this point and yet the business continues to grow generally speaking…”
“Yeah, listen, we continue to be really excited about CF, very proud of the leadership position that we've built over the last 20 years. you know we have an outstanding portfolio of medicines and hundreds of thousands of patient years of experience at this point and yet the business continues to grow generally speaking…”
“I'm pleased to share the details of Vertex's strong financial performance in the fourth quarter and for the full year 2025, which stands as a testament to our market leadership, the strength of our product portfolio, and our disciplined approach to investment and operational management.”
“Vertex's excellent results in the fourth quarter of 2024 demonstrate once again our consistent strong performance and attractive growth profile.”
Biotechnology · Healthcare
CFO
